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Editorial 
This Journal of Controlled Release Special Issue focusses on advances in microneedle technology; 
miniaturised needles whose dimensions permit either the painless and targeted delivery of materials into 
skin for therapeutic purposes or the extraction of biological fluids for sensing purposes. A dedicated 
International Conference on Microneedles was founded in 2010 to provide a forum for the academic and 
industrial community to share research progress, network and educate the next generation of scientists 
working in the field. Following that first meeting, held in Atlanta, U.S.A., the meeting has grown through 
subsequent conferences in 2012 (Cork, Ireland) and 2014 (Baltimore, U.S.A.). This Special Issue of the 
Journal of Controlled Release captures some of the research outputs arising from delegates attending the 
Fourth International Conference on Microneedles, which was co-hosted by Cardiff University and GSK at 
GSK House, London, U.K., from May 23-25th, 2016. More than 250 delegates from 24 countries attended 
this meeting, which brought together academic, industrial and regulatory opinion leaders to consider the 
principal challenges that currently face the microneedle community. 
A series of Presentations, in sessions entitled (i) Vaccine delivery, (ii) Assorted Innovations, (iii) 
Microneedles in the Clinic, (iv) Commercialisation and Regulatory Adoption, (v) Sensors: Devices and 
Diagnostics and (vi) Therapeutic Delivery, provided delegates with a broad understanding of the current 
research landscape. All sessions were concluded with panel sessions, which facilitated robust discussion 
and debate. One clear message was that microneedle technology has reached a critical stage in its 
development, with numerous examples of devices that are transitioning from R&D laboratories to the 
clinical arena. Microneedles are new dosage forms/delivery devices, and so numerous small and major 
pharmaceutical/medical device corporations (47 companies attended the meeting) are currently facing 
common challenges in anticipating and satisfying the regulatory, manufacturing and other development 
hurdles that accompany clinical progress. At the next meeting in 2018 we hope to see progress along the 
clinical pathway and new innovations in microneedle based technology! 
The editors wish to extend their sincere thanks for the generous support of the sponsors of the event:  
Platinum sponsors – Fujifilm (Japan), LTS (Germany) and Endoderma (Republic of Korea); Gold sponsors – 
Raphas (Republic of Korea), 3M (U.S.A) and Nemaura Pharma (U.K.);  Silver sponsors – B&L Biotech (U.S.A),  
Scienion AG (Germany), Corium (U.S.A.),  Inovio Pharmaceuticals Inc (U.S.A.),  Elsevier (The Netherlands) 
and ON Drug Delivery (U.K.) The editors also extend their appreciation to the Steering Committee of the 
International Conference on Microneedles and colleagues who supported the preparation and 
management of the conference, in particular Andrew Fiorini and Dr Xin Zhao. 
Finally, we thank all of the scientific and social contributions of friends and colleagues that made the 
Fourth International Conference on Microneedles such a success, and look forward to meeting you again, 
alongside some new colleagues I am sure, at the Fifth International Conference on Microneedles in 
Vancouver in 2018. 
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